Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

104 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cunningham D, et al. Among authors: harstrick a. N Engl J Med. 2004 Jul 22;351(4):337-45. doi: 10.1056/NEJMoa033025. N Engl J Med. 2004. PMID: 15269313 Free article. Clinical Trial.
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A, Eckardt A. Baselga J, et al. Among authors: harstrick a. J Clin Oncol. 2005 Aug 20;23(24):5568-77. doi: 10.1200/JCO.2005.07.119. Epub 2005 Jul 11. J Clin Oncol. 2005. PMID: 16009950 Clinical Trial.
New systemic frontline treatment for metastatic colorectal carcinoma.
Braun AH, Achterrath W, Wilke H, Vanhoefer U, Harstrick A, Preusser P. Braun AH, et al. Among authors: harstrick a. Cancer. 2004 Apr 15;100(8):1558-77. doi: 10.1002/cncr.20154. Cancer. 2004. PMID: 15073842 Free article. Review.
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, Humblet Y, Lopez-Pousa A, Hitt R, Vega Villegas ME, Duck L, Rosine D, Amellal N, Schueler A, Harstrick A. Bourhis J, et al. Among authors: harstrick a. J Clin Oncol. 2006 Jun 20;24(18):2866-72. doi: 10.1200/JCO.2005.04.3547. Epub 2006 May 22. J Clin Oncol. 2006. PMID: 16717293 Clinical Trial.
Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials.
Schwartz GK, Harstrick A, González Barón M. Schwartz GK, et al. Eur J Cancer. 1999 Mar;35 Suppl 1:S9-13. doi: 10.1016/s0959-8049(99)00042-8. Eur J Cancer. 1999. PMID: 10645208 Clinical Trial.
In the second study, 5-FU was administered as a weekly 24-h infusion for 5 weeks of a 6-week cycle and raltitrexed was given 15-min prior to 5-FU on days 8 and 29. ...Raltitrexed had a significant effect on the pharmacokinetics of 5-FU irrespective of 5-FU re …
In the second study, 5-FU was administered as a weekly 24-h infusion for 5 weeks of a 6-week cycle and raltitrexed was given 1 …
Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
Welt A, von Minckwitz G, Oberhoff C, Borquez D, Schleucher R, Loibl S, Harstrick A, Kaufmann M, Seeber S, Vanhoefer U. Welt A, et al. Among authors: harstrick a. Ann Oncol. 2005 Jan;16(1):64-9. doi: 10.1093/annonc/mdi024. Ann Oncol. 2005. PMID: 15598940 Free article. Clinical Trial.
Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.
Tewes M, Schleucher N, Achterrath W, Wilke HJ, Frings S, Seeber S, Harstrick A, Rustum YM, Vanhoefer U. Tewes M, et al. Ann Oncol. 2003 Sep;14(9):1442-8. doi: 10.1093/annonc/mdg376. Ann Oncol. 2003. PMID: 12954586 Clinical Trial.
For the first two dose levels, irinotecan (70 mg/m(2)) was administered once a week for 6 weeks in combination with 2 weeks of capecitabine at 1000 mg/m(2) (DL1) or 1250 mg/m(2) (DL2) twice daily, starting on days 1 and 22. ...Subsequently, the starting dose (DL1) was exte …
For the first two dose levels, irinotecan (70 mg/m(2)) was administered once a week for 6 weeks in combination with 2 weeks of capeci …
Irinotecan in the treatment of colorectal cancer: clinical overview.
Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Vanhoefer U, et al. J Clin Oncol. 2001 Mar 1;19(5):1501-18. doi: 10.1200/JCO.2001.19.5.1501. J Clin Oncol. 2001. PMID: 11230497 Review.
With the recognition that topoisomerase-I (TOP-I) is an important therapeutic target in cancer therapy, irinotecan, a semisynthetic TOP-I-interactive camptothecin derivative, has been clinically established in the treatment of colorectal cancer. ...
With the recognition that topoisomerase-I (TOP-I) is an important therapeutic target in cancer therapy, irinotecan, a semisynthetic T …
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
Vanhoefer U, Harstrick A, Köhne CH, Achterrath W, Rustum YM, Seeber S, Wilke H. Vanhoefer U, et al. J Clin Oncol. 1999 Mar;17(3):907-13. doi: 10.1200/JCO.1999.17.3.907. J Clin Oncol. 1999. PMID: 10071283 Clinical Trial.
PURPOSE: To determine the maximum-tolerated dose (MTD) of a weekly schedule of irinotecan (CPT-11), leucovorin (LV), and a 24-hour infusion of fluorouracil (5-FU24h) as first-line chemotherapy in advanced colorectal cancer and to assess preliminary data on the antit …
PURPOSE: To determine the maximum-tolerated dose (MTD) of a weekly schedule of irinotecan (CPT-11), leucovorin (LV), and a 24- …
Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer.
Klaassen U, Wilke H, Weyhofen R, Harstrick A, Eberhardt W, Müller C, Korn M, Hanske M, Diergarten K, Seeber S. Klaassen U, et al. Anticancer Drugs. 1998 Mar;9(3):203-7. doi: 10.1097/00001813-199803000-00002. Anticancer Drugs. 1998. PMID: 9625430 Clinical Trial.
Results from our previous phase II study demonstrating high efficacy and low toxicity for a weekly schedule of 5-fluorouracil (5-FU)/leucovorin in intensively pretreated patients with metastatic breast cancer prompted addition of paclitaxel and cisplatin to this regimen fo …
Results from our previous phase II study demonstrating high efficacy and low toxicity for a weekly schedule of 5-fluorouracil (5-FU)/ …
104 results
Jump to page
Feedback